Search Results
Your search for ,maY matches 17054 pages
Showing 11451 - 11500Novel Approaches Harness the Microenvironment Against Hodgkin Lymphoma
In the treatment of classical Hodgkin lymphoma, antibodies targeting programmed cell death protein 1 (PD-1) are just the beginning, according to Stephen M. Ansell, MD, PhD, Professor of Medicine and Chair of the Lymphoma Group at the Mayo Clinic, Rochester, Minnesota.1 Speaking at the 2016 Pan...
Scalp Cooling for Chemotherapy-Induced Alopecia Becoming Mainstream
Hair loss can be a devastating side effect of chemotherapy, but the recent U.S. Food and Drug Administration (FDA) approval of the DigniCap Cooling System and the growing acceptance of scalp-cooling methods in the United States may improve the quality of life for many patients receiving...
ASCO Guideline Addresses Controversial Areas in Adjuvant Therapy for Breast Cancer
ASCO has published an adaptation of the 2015 Cancer Care Ontario (CCO) clinical practice guideline on adjuvant chemotherapy for early-stage breast cancer.1 There were several areas of controversy that the guideline attempts to address. Should Anthracyclines Be Standard of Care? The guideline...
New Upfront Treatment Algorithm Emerges for Chronic Lymphocytic Leukemia
According to Susan M. O’Brien, MD, an expert in the treatment of chronic lymphocytic leukemia (CLL), novel agents and new data on patient subsets have led to a new upfront treatment algorithm for this malignancy. Speaking at the 2016 Pan Pacific Lymphoma Conference in Koloa, Hawaii, Dr. O’Brien...
Have You Received Your Immune Checkpoint Inhibitor Yet?
“Have you received your immune checkpoint inhibitor yet?” I suspect St. Peter may have started asking this question routinely at the Pearly Gates to Heaven. If St. Peter has not, I am sure most oncologists have. With extensive media coverage on the approval of nivolumab (Opdivo) and pembrolizumab...
How the Oncology Center of Excellence Plans to Foster Collaboration Among Researchers to Advance Cancer Treatment
On June 29, 2016, Robert M. Califf, MD, MACC, the Commissioner of the U.S. Food and Drug Administration (FDA), announced the selection of Richard Pazdur, MD, FACP, as Acting Director of the FDA’s newly created Oncology Center of Excellence. The center was created in response to the overarching...
Racial/Ethnic Disparities in Genomic Sequencing
As scientists learn more about which genetic mutations are driving different types of cancer, they're targeting treatments to small numbers of patients, with the potential for big payoffs in improved outcomes. But even as we learn more about these driver mutations, a new study published by Spratt...
Parents May be More Likely to Support HPV Vaccine Requirements for School Entry If States Include Opt-Out Provisions
Parents are more likely to support laws that would make the human papillomavirus (HPV) vaccine mandatory for school entry if their state offers opt-out provisions, according to a study published by Calo et al in Cancer Epidemiology, Biomarkers & Prevention. However, opt-out provisions may...
Expert Point of View: Amir T. Fathi, MD
Amir T. Fathi, MD, an oncologist at the Massachusetts General Hospital Cancer Center and Assistant Professor of Medicine at Harvard Medical School, Boston, commented on the INO-VATE ALL trial for The ASCO Post. “It has been a fairly exciting time for patients with acute lymphoblastic leukemia...
Inotuzumab Ozogamicin Shows Clear Benefit in Acute Lymphoblastic Leukemia
In patients with relapsed/refractory acute lymphoblastic leukemia (ALL), the antibody-drug conjugate inotuzumab ozogamicin produced significantly more complete remissions and was a better bridge to transplant than treatment by physician’s choice, according to the final results of a phase III trial...
Study Links F12 and STC2 Genes to Breast Cancer Survival
Testing for the activity of two genes could help identify women who are at increased risk of dying from breast cancer, according to a new study of almost 2,000 patients. Women whose tumors had a specific pattern of activity in the F12 and STC2 genes were three times as likely to die within 10 years ...
Psychological Impact of Genetic Testing to Be Explored in Subset of NCI-MATCH Trial Patients
The ECOG-ACRIN Cancer Research Group has received federal approval to add a quality-of-life research study, COMmunication and Education in Tumor Profiling, or COMET (EAQ152), to the NCI-MATCH (EAY131) trial already underway. Using feedback surveys before and after a patient undergoes tumor gene...
Bone Marrow–Derived Stem Cells May Offer Blood Transplant Recipients Better Quality of Life
A large, nationwide study published by Lee et al in the journal JAMA Oncology found that patients who received transplants of cells collected from a donor's bone marrow had better self-reported psychological well-being, experienced fewer symptoms of graft-vs-host disease (GVHD), and were more...
Study Finds ‘Bursts’ of Chromosome Changes Fuel Breast Cancer Tumor Growth
As with most cancers, triple-negative breast cancer cells have abnormal amounts of chromosomes or DNA copy number aberrations in their genomes. A new study used single-cell sequencing technology to provide previously unknown details about how and when copy number aberrations impact tumor...
Pulmonary Complications in Adult Survivors of Childhood Cancer
A team of researchers from nine leading academic hospitals and research centers have published a paper in the journal Cancer that describes pulmonary outcomes among childhood cancer survivors. The study also evaluates the impact of complications such as asthma, chronic cough, emphysema, and...
Preclinical Study Finds Etoposide May Damage Developing Ovaries of Female Fetuses
The chemotherapy drug etoposide may have adverse effects on the developing ovaries of female fetuses, according to a preclinical study of mouse cells published by Stefansdottir et al in BMC Cancer. Norah Spears, DPhil, the corresponding study author and Professor of Reproductive Physiology at the...
Breast Density and Risk Factors May Be Useful for Tailoring Breast Cancer Screening for Older Women
A collaborative modeling study evaluating outcomes for various screening intervals for women over the age of 50 based on breast density and risk for breast cancer has found that average-risk women with low breast density undergoing triennial screening and higher-risk women with high breast density...
Leptomeningeal Metastases More Common in NSCLC With EGFR Mutations, May Be Responsive to Tyrosine Kinase Inhibitors
Leptomeningeal metastases, a serious complication in lung cancer patients, were found to be more prevalent in patients with non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. In a recent study of leptomeningeal metastases published by Li et al in...
Immune Analysis of On-Treatment Longitudinal Biopsies Predicts Response to Melanoma Immunotherapy
Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, according to researchers at The University of Texas MD Anderson Cancer Center. Chen et al reported their findings in...
Report Tracks Cancer Trends by Race/Ethnicity in Los Angeles County for 37 Years
Prostate cancer and lung cancer have been the number 1 and 2 cancers among men. Stomach cancer, the third leading cause of cancer deaths worldwide, has been on a steady decline among Koreans and Japanese. Black men had the highest overall rates of cancer. Thyroid cancer has been on the rise, and...
Combining Radium-223 With Other Therapies May Be of Benefit in Metastatic Castration-Resistant Prostate Cancer
In an international, single-arm phase IIIB trial reported in The Lancet Oncology, Saad et al found benefit with the addition of abiraterone (Zytiga) or enzalutamide (Xtandi) to radium-223 (Xofigo) in patients with metastatic castration-resistant prostate cancer. This early-access program was...
New SSO, ASTRO, and ASCO Joint DCIS Consensus Guideline Could Curb Unnecessary Breast Surgery and Reduce Health System Costs
Three leading national cancer organizations have issued a consensus guideline for physicians treating women who have ductal carcinoma in situ (DCIS) treated with breast-conserving surgery and whole breast irradiation. The new guideline has the potential to save many women from unnecessary...
Metabolic Imaging as a Method to Assess Treatment Response to Cytotoxic and Cytostatic Agents
Tumor shrinkage is not the only measure of a successful anticancer therapy. A University of Colorado Cancer Center article published by Serkova et al in Frontiers in Oncology describes a promising alternative: metabolic imaging. Tumors rush their metabolism to grow and proliferate. By recognizing a ...
Study Identifies Novel Treatment Resistance Mechanism in BRAF-Mutant Melanoma
A Massachusetts General Hospital (MGH) research team has identified an additional mechanism for resistance to targeted treatment for BRAF-mutant melanoma. Their findings, published by Shen et al in Nature Medicine, report that inactivating mutations in two genes responsible for regulating key...
Study Finds Venetoclax Monotherapy Safe and Clinically Active in AML
A phase II study has found venetoclax (Venclexta) to be clinically active in patients with high-risk relapsed/refractory acute myelogenous leukemia (AML) or those unfit for intensive chemotherapy, with an overall response rate of 19% and a tolerable safety profile. The study results, which were...
New Study Shows Breast Tumors May Evolve in Response to Hormone Therapy
Many breast tumors grow in response to female hormones, especially estrogen. Drugs that reduce estrogen levels in the body often are effective in reducing tumor size and preventing recurrence of the cancer. But some tumors become resistant to these therapies and continue to grow and spread. A new...
Insurance Status Impacts Survival, According to Two New Studies
Men with testicular cancer who were uninsured or on Medicaid had a higher risk of death from what is normally a curable disease than insured patients, a new study found. The findings, published by Markt et al in Cancer, add to growing evidence that differences in health insurance status can affect...
Chinese Journal of Cancer Collecting 150 Most Important Questions in Cancer Research and Clinical Oncology
The Chinese Journal of Cancer (CJC) is soliciting the 150 most important questions in cancer research and clinical oncology from cancer researchers around the world. The editors of CJC believe this will help provide important insights and guidance in future efforts to advance cancer research...
ASCO and SGO Issue New Guideline on Ovarian Cancer Treatment
ASCO and the Society of Gynecologic Oncology (SGO) today issued a joint clinical practice guideline on ovarian cancer treatment. The guideline provides evidence-based recommendations on whether to use neoadjuvant chemotherapy or surgery as the initial treatment for women with stage IIIC and IV...
Late Effects of Blood and Marrow Transplantation: Consensus Conference Maps Research Directions
More than 60,000 blood and marrow transplants are performed each year worldwide, and the number of long-term survivors is increasing rapidly. But with success has come a host of new issues for patients, providers, and researchers. “Back when transplants were new, the 1-year mortality rate was high, ...
Multiple Strategies for Colorectal Cancer Screening Offer an Opportunity for Shared Decision-Making
Screening for colorectal cancer should start at age 50 and continue until age 75, according to the updated recommendation from the U.S. Preventive Services Task Force (USPSTF).1 “Exactly what screening gets done is something that doctors and patients should decide together,” USPSTF Chair Kirsten...
Multiple Means to Realize the Benefits of Colorectal Cancer Screening
In an updated recommendation statement, the U.S. Preventive Services Task Force (USPSTF) continues to strongly recommend screening for colorectal cancer for asymptomatic adults aged 50 through 75; but rather than emphasize specific screening strategies, it notes there are multiple screening...
FDA Approves Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Platinum-Containing Chemotherapy
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda), an anti–PD-1 (programmed cell death protein 1) therapy, at a fixed dose of 200 mg every 3 weeks, for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma with...
The Building Block of Life, Brick by Brick
BookmarkTitle: The Gene: An Intimate HistoryAuthor: Siddhartha Mukherjee, MDPublisher: ScribnerPublication date: May 2016Price: $32.00; hardcover, 608 pagesOn February 28, 1953, James Watson and Francis Crick entered The Eagle, a favorite watering hole for researchers working at the University of...
David LeDuc Named Executive Director of Addario Lung Cancer Foundation
The Bonnie J. Addario Lung Cancer Foundation (ALCF) has announced that it has appointed David LeDuc as its new Executive Director. Mr. LeDuc most recently served as the Senior Director of Strategic Alliances for the Addario Lung Cancer Medical Institute (ALCMI), a partner foundation to ALCF, where ...
Photonics and the Cancer Moonshot Initiative: Partnership Highlights Role of Technology and IT Infrastructure in Reaching Goals
Photonics—the science of light—may not be associated with cancer in most people’s minds. But photonic technologies are: CT (computed tomography) scans and digital x-rays, for instance, are in everyday use, and next-generation oncology applications are in development. As the White House’s National...
Measures of Success
I was raised to be an engineer. I grew up in an industrial community, worked summer jobs in a U.S. Steel chemical plant, and was good at science and math. My career choice was straightforward: I went to an engineering university. My first semester freshman year included a mandatory introduction...
Integrating Early Palliative Medicine Into Oncology Care to Improve Patients’ Quality of Life
At the 2015 Palliative Care in Oncology Symposium in Boston, Vicki Jackson, MD, MPH, Chief in the Division of Palliative Care and Geriatrics at Massachusetts General Hospital, Co-Director of the Harvard Center for Palliative Care, and Associate Professor of Medicine at Harvard Medical School,...
FDA Approves Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C Virus Infection
The U.S. Food and Drug Administration (FDA) approved Epclusa (sofosbuvir at 400 mg/velpatasvir at 100 mg) on June 28, 2016, to treat adult patients with chronic hepatitis C virus both with and without cirrhosis. For patients with moderate to severe cirrhosis (decompensated cirrhosis),...
FDA Approves First HPV Test for Use With SurePath Preservative Fluid
On July 7, 2016, the U.S. Food and Drug Administration (FDA) approved the Roche cobas HPV Test as the first test for human papillomavirus (HPV) that can be used with cervical cells obtained for a Papanicolau (Pap) test and collected in SurePath Preservative Fluid. The FDA approves HPV tests to be...
NCI Awards $12 Million for Multi-Institution Breast Cancer Genetics Study
A large study headed by researchers from the Keck School of Medicine of the University of Southern California (USC), Vanderbilt University, and Boston University received $12 million in funding to examine why African American women die at a higher rate from breast cancer and have more aggressive...
New Analysis Shows Advertising by U.S. Cancer Centers Has Soared Over Past Decade
American cancer centers promoting their services dramatically increased their advertising spending from 2005 to 2014, with the bulk of the spending by for-profit organizations, according to the results of a study published by Vater et al in JAMA Internal Medicine.1 Small Percentage Responsible for...
Actively Recruiting Clinical Trials Focused on the Role of Obesity in Cancer
Study Title: A Pilot Study of a Protein-Sparing Modified Fast for Weight Loss in Obese Endometrial Cancer Survivors Study Type: Pilot/interventional/single-group assignment Study Sponsor and Collaborators: Case Comprehensive Cancer Center, National Cancer Institute Purpose: To study whether the...
Educating People About Clinical Trials May Improve Their Likelihood of Participation
The facts are well known: Although clinical trials are regarded as the gold standard to investigate whether a new treatment is safe and effective in patients—and have resulted in advances in cancer cures and increases in cancer survivorship—only 3% to 5% of patients enroll in these studies.1 The...
Making a Difference in the Lives of Others
Quyen D. Chu, MD, MBA, FACS, this year’s recipient of ASCO’s Humanitarian Award, lives by the axiom that “One person can make a positive difference in the lives of others.” Although the term has become cliché, the experiences in Dr. Chu’s life and oncology career prove just how profound and...
Androgen-Deprivation Therapy May Increase Mortality in African American Men With Favorable-Risk Prostate Cancer
In a retrospective study analyzing patients' medical records, researchers at Brigham and Women's Hospital (BWH) found that race significantly affected longevity by increasing the likelihood of death after receiving androgen-deprivation therapy. These findings were published by Kovtun et al in...
Metabolic Gene-Expression Profile May Identify Kidney Cancer Patients Unlikely to Benefit From Nivolumab
Renal cell carcinomas (RCC) positive for the protein programmed death ligand 1 (PD-L1) from patients who did not respond to treatment with the anti–PD-1 therapeutic nivolumab (Opdivo) had significantly higher expression of genes associated with metabolism, compared with PD-L1–positive...
Genetic Characteristics of Recurrent and Metastatic Head and Neck Cancers
Next-generation sequencing of recurrent or metastatic head and neck tumors at Memorial Sloan Kettering Cancer Center (MSK) has provided insight into the molecular characteristics of these tumors, which may aid in the implementation of precision treatment. Morris et al reported these findings in...
High-Intensity Local Treatment May Improve Survival in Patients With Metastatic Urothelial Carcinoma of the Bladder
In a National Cancer Data Base analysis reported in the Journal of Clinical Oncology, Seisen et al found that high-intensity local treatment was associated with an overall survival benefit in patients with metastatic urothelial carcinoma of the bladder. Study Details The study included data from...
Is Post-Transplantation Cyclophosphamide Disruptive Technology?
There was a time when transplantation across human leukocyte antigen (HLA) barriers was fraught with so much difficulty that many thought it was impossible and we should stop trying. However, most patients do not have an HLA-matched sibling donor, and death was therefore certain if they had a...
